The Food and Drug Administration announced plans to speed the market entry of generic drugs, including a new regulation that limits brand-name drugmakers to one 30-month "stay" for settling patent challenges. The FDA also said it will revamp its approval process for generic drugs and expects to reduce the time required to approve most generic drugs by three months or more over the next three to five years. HHS officials estimated the changes would save consumers $35 billion over 10 years. The new regulations will be published in the June 18 Federal Register and take effect Aug. 18. -- by Cinda Becker
FDA alters rules to speed availability of generics
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.